# US 2016/0243213 A9 · Recombinant Protein Bodies as Immunogen-Specific Adjuvants

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0243213 A9
- Document ID: US20160243213A9
- Status: Published application
- Kind: A9
- Application number: 13/123,510
- Filed: 2009-10-09
- Published: 2016-08-25
- Earliest claimed: 2006-02-23
- Assignees: Era Biotech, S.A.
- Inventors: Edward Peter Rybicki; Ann Elizabeth Meyers; François Devesa; Pablo Marzábal Luna; Inga Isabel Hitzeroth; Peter Öhlschläger
- Web page: https://patentgrep.com/patent/US20160243213A9

## CPC

- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61P 31/18: for HIV
- A61K 39/12: Viral antigens
- A61K 39/385: Haptens or antigens, bound to carriers
- A61P 31/20: for DNA viruses
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/005: from viruses
- C07K 14/415: from plants
- C07K 14/425: Zeins
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/625: {containing a sequence coding for a signal sequence}
- C12N 15/8216: {Methods for controlling, regulating or enhancing expression of transgenes in plant cells}
- C12N 15/8218: {Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]}
- C12N 15/8257: {for the production of primary gene products, e.g. pharmaceutical products, interferon}
- C12N 15/8258: {for the production of oral vaccines (antigens) or immunoglobulins}
- A61K 2039/5258: {Virus-like particles}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/572: {cytotoxic response}
- A61K 2039/575: {humoral response}
- A61K 2039/585: {wherein the target is cancer}
- A61K 2039/6031: {Proteins}
- C07K 2319/04: containing an ER retention signal such as a C-terminal HDEL motif
- C12N 2710/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2710/20071: Demonstrated in vivo effect
- C12N 2740/16022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

An immunogen-specific is adjuvant for a vaccine or inoculum is disclosed. The adjuvant is comprised of particulate recombinant protein body-like assemblies (RPBLAs) that contain a recombinant fusion protein that contains two portions peptide-linked together. A first portion is a protein body-inducing sequence (PBIS) and a second portion is a T-cell stimulating immunogenic polypeptide whose sequence is that of a pathogenic polypeptide sequence present in or induced by a vaccine or inoculum. The adjuvant, when used as an inoculum in a host animal without a prior priming vaccination or inoculation, does not induce production of antibodies or T cell activation to the pathogenic sequence.

## Claims

### Claim 1

A method for inducing a T-cell mediated immune response in a subject in need thereof against an immunogenic peptide, the method comprising administration to a subject in need thereof of a vaccine comprising (i) a particulate recombinant protein body-like assembly (RPBLA) that comprises a recombinant fusion protein, said recombinant fusion protein comprising a protein body-inducing sequence (PBIS) and an immunogenic polypeptide or (ii) a nucleic acid molecule that encodes a recombinant fusion protein, said recombinant fusion protein comprising a protein body-inducing sequence (PBIS) and an immunogenic polypeptide.

### Claim 2 (depends on 1)

The method as defined in claim 1 wherein the PBIS comprises a prolamin.

### Claim 3 (depends on 2)

The method as defined in claim 2 wherein the prolamin is selected from the group consisting of ganuna-zein, alpha-zein, delta-zein, beta-zein, rice prolamin and gamma-gliadin.

### Claim 4 (depends on 1)

The method as defined in claim 1 wherein the PBIS sequence further comprises a signal peptide sequence.

### Claim 5 (depends on 1)

The method as defined in claim 1 wherein the immunogenic polypeptide sequence is selected from the group consisting of (i) a polypeptide encoded by the HPV E7 gene, (ii) a polypeptide encoded by the HIV-1 gag, gene and (iii) a polypeptide encoded by the HIV-1 p01 gene.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The method as defined in claim 1 wherein the administration is preceded by administration of a priming vaccination or inoculation using a composition comprising the immunogenic polypeptide or a nucleic acid encoding the immunogenic polypeptide.

### Claim 8 (depends on 7)

The method as defined in claim 7 wherein the composition comprising the immunogenic polypeptide used in the priming vaccination or inoculation is selected from the group consisting of
(i) a particulate recombinant protein body-like assembly (RPBLA) comprising a recombinant fusion protein, said recombinant fusion protein comprising a protein body-inducing sequence (PBIS) and an immunogenic polypeptide,
(ii) a: nucleic acid molecule that encodes the immunogenic polypeptide and
(iii) a nucleic acid molecule that encodes a recombinant fusion protein, said recombinant fusion protein containing a protein body-inducing sequence (PBIS) and the immunogenic polypeptide.

### Claim 9 (depends on 1)

The method as defined in claim 1 wherein the vaccine is administered intramuscularly.

### Claim 10

An immunogen-specific adjuvant for a vaccine or inoculum comprising a particulate recombinant protein body-like assembly (RPBLA) comprising a recombinant fusion protein, said recombinant fusion protein comprising a protein body-inducing sequence (PBIS) and a T-cell stimulating immunogenic polypeptide whose sequence is that of a pathogenic polypeptide sequence present in or induced by a vaccine or inoculum, said adjuvant at the concentration used in an inoculum without a prior priming vaccination or inoculation not inducing production of antibodies or T cell activation to the pathogenic sequence.

### Claim 11 (depends on 10)

The immunogen-specific adjuvant according to claim 10, whose PBIS comprises a prolamin.

### Claim 12 (depends on 10)

The immunogen-specific adjuvant according to claim 10, whose PBIS further comprises a signal peptide.

### Claim 13 (depends on 11)

The immunogen-specific adjuvant according to claim 11, wherein said prolamin is selected from the group consisting of gamma-zein, alpha-zein, delta-zein, beta-zein, rice prolamin and gamma-gliadin.

### Claim 14 (depends on 10)

The immunogen-specific adjuvant according to claim 10, wherein said T-cell stimulating immunogenic polypeptide sequence is encoded by the HPV E7 gene.

### Claim 15 (depends on 10)

The immunogen-specific adjuvant according to claim 10, wherein said T-cell stimulating immunogenic polypeptide sequence is present in HIV-1.

### Claim 16 (depends on 15)

The immunogen-specific adjuvant according to claim 15, wherein the polypeptide present in HIV-1 is encoded by the HIV-1 gag gene.

### Claim 17

(canceled)

### Claim 18 (depends on 10)

An adjuvant composition comprising the adjuvant according to claim 10 present in an adjuvant-effective amount dissolved or dispersed in a pharmaceutically acceptable diluent.

### Claim 19 (depends on 18)

The adjuvant composition according to claim 18, wherein the diluent is aqueous-based.

### Claim 20

An immunogen-specific adjuvant for a vaccine or inoculum that is comprised of a nucleic acid molecule that encodes a recombinant fusion protein, said recombinant fusion protein comprising a protein body-inducing sequence (PBIS) and a T-cell stimulating immunogenic polypeptide whose sequence is that of a pathogenic polypeptide sequence present in or induced by a vaccine or inoculum, said adjuvant when used as an inoculum without a prior priming vaccination or inoculation not inducing production of antibodies or T cell activation to the pathogenic sequence.

### Claim 21 (depends on 20)

The immunogen-specific adjuvant according to claim 20, wherein the PBIS comprises a prolamin.

### Claim 22 (depends on 20)

The immunogen-specific adjuvant according to claim 20, wherein the PBIS further comprises a signal peptide.

### Claim 23 (depends on 21)

The immunogen-specific adjuvant according to claim 21, wherein said prolamin selected from the group consisting of gamma-zein, alpha-zein, delta-zein; beta-zein, rice prolamin and gamma-gliadin.

### Claim 24

A vaccine or inoculum comprising a nucleic acid molecule that encodes a recombinant fusion protein, said recombinant fusion protein comprising a protein body-inducing sequence (PBIS) and an immunogenic polypeptide.
